Association of CYP2E1 gene polymorphism with predisposition to cancer development

Experimental Oncology

Volumn 27, Issue 4, 2005, Pages 248-256

  Danko, I M ^a   Chaschin, N A ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

Author keywords

Cytochrome P450 2E1; Gene polymorphism; Genetic susceptibility

Indexed keywords

ANILINE DERIVATIVE; CARCINOGEN; CYTOCHROME P450 2E1; MESSENGER RNA; NITROSAMINE; TOBACCO SMOKE; URETHAN; VINYL CHLORIDE;

CANCER RISK; CANCER SUSCEPTIBILITY; CHEMICAL CARCINOGENESIS; CIGARETTE SMOKING; DNA DAMAGE; ESOPHAGUS CANCER; ETHNIC GROUP; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT TRANSFORMATION; NASOPHARYNX CANCER; REVIEW; STOMACH CANCER;

CELL TRANSFORMATION, NEOPLASTIC; CYTOCHROME P-450 CYP2E1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 31344450121     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4: 168-79.
2. Camus AM, Geneste O, Honkakoski P, Bereziat JC, Henderson CJ, Wolf CR, Bartsch H, Lang MA. High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol Carcinog 1993; 7: 268-75.
3. Tanaka E, Terada M, Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther 2000; 25: 165-75.
4. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 2000; 9: 3-28.
5. Umeno M, McBride OW, Yang CS, Gelboin HV, Gonzalez FJ. Human ethanol-inducible P450IIE1: complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry 1988; 27: 9006-13.
6. Ingelman-Sundberg M, Johansson I, Yin H, Terelius Y, Eliasson E, Clot P, Albano E. Ethanol-inducible cytochrome P4502E1: genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol 1993; 10: 447-52.
7. Goasduff T, Bellec G, Amet Y, Dreano Y, Menez JF, Berthou F. P450 2E1 expression in liver, kidney, and lung of rats treated with single or combined inducers. Alcohol 1996; 13: 301-8.
8. Nakajima T, Aoyama T. Polymorphism of drug-metabolizing enzymes in relation to individual susceptibility to industrial chemicals. Ind Health 2000; 38: 143-52.
9. Lewis DF, Bird MG, Parke DV. Molecular modelling of CYP2E1 enzymes from rat, mouse and man: an explanation for species differences in butadiene metabolism and potential carcinogenicity, and rationalization of CYP2E substrate specificity. Toxicology 1997; 118: 93-13.
10. Wang AH, Sun CS, Li LS, Huang JY, Chen QS. Relationship of tobacco smoking, CYP 1A1, GSTM1 gene polymorphism and esophageal cancer in Xi'an. World J Gastroenterol 2002; 113: 49-53.
11. Hu Y, Oscarson M, Johansson I, Yue QY, Dahl ML, Tabone M, Arinco S, Albano E, Ingelman-Sundberg M. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol Pharmacol 1997; 51: 370-6.
12. Lucas D, Farez C, Bardou LG, Vaisse J, Attali JR, Valensi P. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 1998; 12: 553-8.
13. McCarver DG, Byun R, Hines RN, Hichme M, Wegenek W. A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 1998; 152: 276-81.
14. Park KS, Sohn DH, Veech RL, Song BJ. Translational activation of ethanol-inducible cytochrome P450 (CYP2E1) by isoniazid. Eur J Pharmacol 1993; 248: 7-14.
15. Gebhardt AC, Lucas D, Menez JF, Seitz HK. Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology 1997; 26: 957-61.
16. Powell H, Kitteringham NR, Pirmohamed M, Smith DA, Park BK. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. Pharmacogenetics 1998; 8: 411-21.
17. Kato S, Tajiri T, Matsukura N, Matsuda N, Taniai N, Mamada H, Yoshida H, Kiyam T, Naito Z. Genetic polymorphisms of aldehyde dehydrogenase 2, cytochrome p450 2E1 for liver cancer risk in HCV antibody-positive Japanese patients and the variations of CYP2E1 mRNA expression levels in the liver due to its polymorphism. Scand J Gastroenterol 2003; 38: 886-93.
18. Yoo JS, Guengerich FP, Yang CS. Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res 1988; 48: 1499-504.
19. Kim RB, O'Shea D. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphism. Clin Pharmacol Ther 1995; 57: 645-55.
20. Ingelman-Sundberg M, Oscarson M, Daly AK, Garte S, Nebert DW. Human cytochrome P-450 (CYP) genes: a web page for the nomenclature of alleles. Cancer Epidemiol Biomarkers Prev 2001; 10: 1307-8.
21. Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M. Structural and functional characterization of the 5′-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene. Biochem Biophys Res Commun 1999; 263: 286-93.
22. Watanabe J, Hayashi S, Nakachi K, Imai K, Suda Y, Sekine T, Kawajiri K. PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Res 1990; 18: 7194.
23. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem (Tokyo) 1991; 110: 559-65.
24. Kato S, Shields PG, Caporaso NE, Hoover RN, Trump BF, Sugimura H, Weston A, Harris CC. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 1992; 52: 6712-5.
25. Tan W, Song N, Wang GQ, Liu Q, Tang HJ, Kadlubar FF, Lin DX. Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferases M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiol Biomarkers Prev 2000; 9: 551-6.
26. Carriere V, Berthou F, Baird S, Belloc C, Beaune P, de Waziers I. Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 1996; 6: 203-11.
27. Wu X, Shi H, Jiang H, Kemp B, Hong WK, Delclos GL, Spitz MR. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis 1997; 18: 967-73.
28. London SJ, Daly AK, Cooper J, Carpenter CL, Navidi WC, Ding L, Idle JR. Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles County. Pharmacogenetics 1996; 6: 151-8.
29. Hildesheim A, Chen CJ, Caporaso NE, Cheng YJ, Hoover RN, Hsu MM, Levine PH, Chen IH, Chen JY, Yang CS, et al. Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: results from a case-control study conducted in Taiwan. Cancer Epidemiol Biomarkers Prev 1995; 4: 607-10.
30. Watanabe J, Hayashi S, Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region. J Biochem (Tokyo) 1994; 116: 321-6.
31. Nomura F, Itoga S, Uchimoto T, Tomonaga T, Nezu M, Shimada H, Ochiai T. Transcriptional activity of the tandem repeat polymorphism in the 5′-flanking region of the human CYP2E1 gene. Alcohol Clin Exp Res 2003; 27: 42S-6.
32. Le Marchand L, Donlon T, Seifried A, Wilkens LR. Red meat intake, CYP2E1 genetic polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 1019-24.
33. Nishimoto IN, Hanaoka T, Sugimura H, Nagura K, Ihara M, Li XJ, And T, Hamada GS, Kowalski LP, Tsugane S. Cytochrome P450 2E1 polymorphism in gastric cancer in Brazil: case-control studies of Japanese Brazilians and non-Japanese Brazilians. Cancer Epidemiol Biomarkers Prev 2000; 9: 675-80.
34. Persson I, Johansson I, Bergling H, Dahl ML, Seidegard J, Rylander R, Rannug A, Hogberg J, Sundberg MI. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 1993; 319: 207-11.
35. Fairbrother KS, Grove J, de Waziers I, Steimel DT, Day CP, Crespi CL, Daly AK. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 1998; 8: 543-52.
36. McBride OW, Umeno M, Gelboin HV, Gonzalez FJ. A Taq I polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). Nucleic Acids Res 1987; 23: 10071.
37. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I, Watanabe M. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 1991; 82: 254-6.
38. Stephens EA, Taylor JA, Kaplan N, Yang CH, Hsieh LL, Lucier GW, Bell DA. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 1994; 4: 185-92.
39. Itoga S, Nomura F, Makino Y, Tomonaga T, Shimada H, Ochiai T, Iizasa T, Baba M, Fujisawa T, Harada S. Tandem repeat polymorphism of the CYP2E1 gene: an association study with esophageal cancer and lung cancer. Alcohol Clin Exp Res 2002; 26: 15S-19S.
40. Cai L, Yu SZ, Zhan ZF. Cytochrome P450 2E1 genetic polymorphism and gastric cancer in Changle, Fujian Province. World J Gastroenterol 2001; 7: 792-5.
41. Guslitser LN. Epidemiology of tumors: the main results of the studies carried in R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology NAS of Ukraine. Exp Oncol 2001; 23: 229-35 (In Russian).
42. Gao C, Takezaki T, Wu J, Li Z, Wang J, Ding J, Liu Y, Hu X, Xu T, Tajima K, Sugimura H. Interaction between cytochrome P-4502E1 polymorphisms and environmental factors with risk of esophageal and stomach cancers in Chinese. Cancer Epidemiol Biomarkers Prev 2002; 11: 29-34.
43. Persson I, Johansson I, Lou YC, Yue QY, Duan LS, Bertilsson L, Ingelman-Sundberg M. Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. Int J Cancer 1999; 81: 325-9.
44. Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol 1993; 22: 1189-92.
45. Lin DX, Tang YM, Peng Q, Lu SX, Ambrosone CB, Kadlubar FF. Susceptibility to esophageal cancer and genetic polymorphisms inglutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol Biomarkers Prev 1998; 7: 1013-8.
46. Xing D, Tan W, Lin D. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population. Oncol Rep 2003; 10: 1615-23.
47. Lu XM, Zhang YM, Lin RY, Arzi G, Wang X, Zhang YL, Zhang Y, Wang Y, Wen H. Relationship between genetic polymorphisms of metabolizing enzymes CYP2E1, GSTM1 and Kazakh's esophageal squamous cell cancer in Xinjiang, China. World J Gastroenterol 2005; 28: 3651-4.
48. Morita S, Yano M, Shiozaki H, Tsujinaka T, Ebisui C, Morimoto T, Kishibuti M, Fujita J, Ogawa A, Taniguchi M, Inoue M, Tamura S, Yamazaki K, Kikkawa N, Mizunoya S, Monden M. CYP1A1, CYP2E1 and GSTM1 polymorphisms are not associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 1997; 71: 192-5.
49. Hung HC, Chuang J, Chien YC, Chern HD, Chiang CP, Kuo YS, Hildesheim A, Chen CJ. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 901-5.
50. Li D, Dandara C, Parker MI. Association of cytochrome P450 2E1 genetic polymorphisms with squamous cell carcinoma of the oesophagus. Clin Chem Lab Med 2005; 43: 370-5.
51. Hildesheim A, Anderson LM, Chen CJ, Cheng YJ, Brinton LA, Daly AK, Reed CD, Chen IH, Caporaso NE, Hsu MM. CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 1997; 89: 1207-12.
52. Kongruttanachok N, Sukdikul S, Setavarin S, Kerekhjanarong V, Supiyaphun P, Voravud N, Poovorawan Y, Mutirangura A. Cytochrome P450 2E1 polymorphism and nasopharyngeal carcinoma development in Thailand: a correlative study. BMC Cancer 2001; 1: 4.
53. Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Daw YF, Chen CJ. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 1995; 109: 1266-73.
54. Yu SZ, Huang XE, Koide T, Cheng G, Chen GC, Harada K, Ueno Y, Sueoka E, Oda H, Tashiro F, Mizokami M, Ohno T, Xiang J, Tokudome S. Hepatitis B and C viruses infection, lifestyle and genetic polymorphisms as risk factors for hepatocellular carcinoma in Haimen, China. Jpn J Cancer Res 2002; 93: 1287-92.
55. Ladero JM, Agundez JA, Rodriguez-Lescure A, Diaz-Rubio M, Benitez J. RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma. Gut 1996; 39: 330-3.
56. Munaka M, Kohshi K, Kawamoto T, Takasawa S, Nagata N, Itoh H, Oda S, Katoh T. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol 2003; 129: 355-60.
57. Kato S, Onda M, Matsukura N, Tokunaga A, Tajiri T, Kim DY, Tsuruta H, Matsuda N, Yamashita K, Shields PG. Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case-control study of gastric cancer and liver disease. Pharmacogenetics 1995; 5: S141-4.
58. Lee HS, Yoon JH, Kamimura S, Iwata K, Watanabe H, Kim CY. Lack of association of cytochrome P450 2E1 genetic polymorphisms with the risk of human hepatocellular carcinoma. Int J Cancer 1997; 71: 737-40.
59. Wong NA, Rae F, Simpson KJ, Murray GD, Harrison DJ. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol Pathol 2000; 53: 88-93.
60. Wu MS, Chen CJ, Dn MT, Wang HP, Shun CT, Sheu JC, Lin JT. Genetic polymorphisms of cytochrome p450 2E1, glutathione S-transferase M1 and T1, and susceptibility to gastric carcinoma in Taiwan. Int J Colorectal Dis 2002; 17: 338-43.
61. Park GT, Lee OY, Kwon SJ, Lee CG, Yoon BC, Hahm JS, Lee MH, Hoo Lee D, Kee CS, Sun HS. Analysis of CYP2E1 polymorphism for the determination of genetic susceptibility to gastric cancer in Koreans. J Gastroenterol Hepatol 2003; 18: 1257-63.
62. You WC, Hong JY, Zhang L, Pan KF, Pee D, Li JY, Ma JL, Rothman N, Caporaso N, Fraumeni JF Jr, Xu GW, Gail MH. Genetic polymorphisms of CYP2E1, GSTT1, GSTP1, GSTM1, ALDH2, and ODC and the risk of advanced precancerous gastric lesions in a Chinese population. Cancer Epidemiol Biomarkers Prev 2005; 14: 451-8.
63. Tsukino H, Kuroda Y, Qiu D, Nakao H, Imai H, Katoh T. Effects of cytochrome P450 (CYP) 2A6 gene deletion and CYP2E1 genotypes on gastric adenocarcinoma. Int J Cancer 2002; 100: 425-8.
64. Colombo J, Rossit AR, Caetano A, Borim AA, Wornrath D, Silva AE. GSTT1, GSTM1 and CYP2E1 genetic polymorphisms in gastric cancer and chronic gastritis in a Brazilian population. World J Gastroenterol 2004; 10: 1240-5.
65. Suzuki S, Muroishi Y, Nakanishi I, Oda Y. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer. J Gastroenterol 2004; 39: 220-30.
66. Uematsu F, Ikawa S, Kikuchi H, Sagami I, Kanamaru R, Abe T, Satoh K, Motomiya M, Watanabe M. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450 IIE1) gene and susceptibility to lung cancer possible relevance to low smoking exposure. Pharmacogenetics 1994; 4: 58-63.
67. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Vainio H. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 1993; 14: 85-8.
68. Quinones L, Lucas D, Godoy J, Caceres D, Berthou F, Varela N, Lee K, Acevedo C, Martinez L, Aguilera AM, Gil L. CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett 2001; 174: 35-44.
69. Wu X, Amos CI, Kemp BL, Shi H, Jiang H, Wan Y, Spitz MR. Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations. Cancer Epidemiol Biomarkers Prev 1998; 7: 13-8.
70. Li Z, Tan W, Shao K. Susceptibility to lung cancer in Chinese is associated with genetic polymorphism in cytochrome P4502E1. Zhonghua Zhong Liu Za Zhi 2000; 22: 5-7.
71. Wang J, Deng Y, Li L, Kuriki K, Ding J, Pan X, Zhuge X, Jiang J, Luo C, Lin P, Tokudome S. Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocarcinoma: a case-control study in Chinese population. Cancer Sci 2003; 94: 448-52.
72. Oyama T, Kawamoto T, Mizoue T, Sugio K, Kodama Y, Mitsudomi T, Yasumoto K. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res 1997; 17: 583-7.
73. Oyama T, Kawamoto T, Matsumoto A, Isse T, Ozaki S, Yasumoto K. Evidence based prevention (EBP): evidence-based approach to prevention of lung cancer by application of cytochrome 2E1 polymorphism. J UOEH 2002; 24: 413-21.
74. El-Zein RA, Zwischenberger JB, Abdel-Rahman SZ, Sankar AB, Au WW. Polymorphism of metabolizing genes and lung cancer histology: prevalence of CYP2E1 in adenocarcinoma. Cancer Lett 1997; 112: 71-8.
75. Farker K, Lehmann MH, Kastner R, Weber J, Janitzky V, Schubert J, Hoffmann A. CYP2E1 genotyping in renal cell/urothelial cancer patients in comparison with control populations. Int J Clin Pharmacol Ther 2000; 38: 30-4.
76. Mittal RD, Srivastava DS. Genetic polymorphism of drug metabolizing enzymes (CYP2E1, GSTP1) and susceptibility to bladder cancer in North India. Asian Pac J Cancer Prev 2005; 6: 6-9.
77. Kiss I, Sandor J, Pajkos G, Bogner B, Hegedus G, Ember I. Colorectal cancer risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-transferase M1 enzymes. Anticancer Res 2000; 20: 519-22.
78. Yu WP, Chen K, Ma XY, Yao KY, Jiang QT, Zou Y, Zhou HG. Genetic polymorphism in cytochrome P450 2E1, salted food and colorectal cancer susceptibility: a case-control study. Zhonghua Yu Fang Yi Xue Za Zhi 2004; 38: 162-6.
79. Liu S, Park JY, Schantz SP, Stern JC, Lazarus P. Elucidation of CYP2E1 5′ regulatory RsaI/Pstl allelic variants and their role in risk for oral cancer. Oral Oncol 2001; 37: 437-45
80. Bouchardy C, Hirvonen A, Coutelle C, Ward PJ, Dayer P, Benhamou S. Role of alcohol dehydrogenase 3 and cytochrome P450 2E1 genotypes in susceptibility to cancers of the upper aerodigestive tract. Int J Cancer 2000; 87: 734-40.
81. Matthias C, Bockmuhl U, Jahnke V, Jones PW, Hayes JD, Alldersea J, Gilford J, Bailey L, Bath J, Worrall SF, Hand P, Fryer AA, Strange RC. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics 1998; 8: 91-100.
82. Neuhaus T, Ko YD, Lorenzen K, Fronhoffs S, Harth V, Brode P, Vetter H, Bolt HM, Pesch B, Bruning T. Association of cytochrome P450 2E1 polymorphisms and head and neck squamous cell cancer. Toxicol Lett 2004; 151: 273-82.
83. Lee HC, Yoon YB, Kim CY. Association between genetic polymorphisms of the cytochromes P-450 (1A1, 2D6, and 2E1) and the susceptibility to pancreatic cancer. Korean J Intern Med 1997; 12: 128-36.